Not a real patient

A CLEAR CHOICE for Ongoing Acne Management

AKLIEF® (triferotene) Cream, 0.005% has proven long-term tolerability for ongoing use.¹

AKLIEF Cream is a well-tolerated therapy your patients can start and stay on

In a 52-week long-term safety study, AKLIEF Cream demonstrated a favorable tolerability profile, with 95% of patients remaining on therapy through Week 52. Patients using AKLIEF Cream experienced a 2-fold improvement in quality of life during the study period.2

Long-term safety and tolerability demonstrated through 52 weeks of AKLIEF Cream treatment

In a 52-week, open-label study of patients with moderate facial and truncal acne, AKLIEF Cream demonstrated sustained tolerability on the face and trunk.²ab Mean scores for erythema, scaling, dryness, and stinging/burning never exceeded mild, peaked at Week 1, and declined thereafter.²ab Treatment compliance remained high throughout the study, supporting long-term use.²ab

Setting patients up for success with AKLIEF Cream

Helping patients establish the right routine from day one can support adherence and optimize the treatment experience.¹ By setting clear expectations around application, skincare, and sun protection, healthcare providers can help patients confidently incorporate AKLIEF Cream into their daily regimen and stay on track with treatment.¹

Once daily application 

AKLIEF Cream is designed for daily use. Encourage patients to apply only a thin layer to skin, as more product does not improve results. 1 pump is sufficient for the face, and 2 pumps are sufficient for the chest and back.1

Set expectations

Set clear expectations for daily use, tolerability, and the time needed to see results. Early counseling may help patients stay engaged with treatment and support long-term adherence.1

Moisturize and protect

Although AKLIEF Cream has a nourishing vehicle, patients should be advised to moisturize as needed and use SPF or other sun protection measures daily.1

Download Patient Instructions
Explore Resources for Your Office and Patients

a. Studied in acne patients from 9 to 58 years of age with diverse skin types and moderate-to-severe acne. Nodulocystic acne was excluded from the trials.

b. Significant improvement seen as early as Week 1 in the pivotal clinical trials.

References

  1. AKLIEF (trifarotene) cream, 0.005% [Prescribing Information]. Dallas, TX: Galderma Laboratories, L.P.
  2. Blume-Peytavi U, Fowler J, Kemény L, et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne: a 52-week multicentre, open-label, single-arm, Phase IIIb study. J Eur Acad Dermatol Venereol. 2020;34(1):166–173.

IMPORTANT SAFETY INFORMATION

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings/Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.